Hydromorphon Stada (Hydromorphone Hydrochloride)

Hydromorphone binds strongly to µ‑opioid receptors in the brain and spinal cord. This activation blocks the transmission of pain signals, reduces neuronal excitability, and raises the threshold for pain perception, producing both analgesia and sedation.

The specific dose of Hydromorphon Stada is individualized. A qualified prescriber determines the appropriate strength, frequency, and duration based on the patient’s pain severity, prior opioid exposure, and overall health status.

Safety data for hydromorphone in pregnancy and lactation are limited. Because opioids can affect fetal development and may be excreted in breast milk, the drug is generally avoided unless the potential benefit justifies the potential risk.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Hydromorphone is more potent on a milligram‑per‑milligram basis than morphine, allowing lower doses for equivalent analgesia. It has a shorter half‑life, which may provide more flexible dosing, but both share similar opioid‑related risks and require careful monitoring.

Store the tablets at ambient temperature below 25 °C, in the original container, protected from moisture and direct light. Keep out of reach of children and do not use if the packaging is damaged.

Hydromorphon Stada is taken orally. Swallow the tablet whole with a full glass of water; do not crush, chew, or split unless specifically instructed by a healthcare professional.

The most critical risks include respiratory depression, severe hypotension, profound sedation, dependence or addiction, and rare allergic reactions such as anaphylaxis. Immediate medical attention is required if breathing becomes shallow or the patient experiences extreme drowsiness.

Patients with known hypersensitivity to hydromorphone or any component of the formulation, those with severe respiratory insufficiency, acute or severe asthma, or paralytic ileus should avoid this medication. It is also contraindicated in individuals taking MAO inhibitors within the past 14 days.